Manila Times Business
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer
New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus hormone therapy compared with immediate surgery1Twice as many patients remained free from subsequent treatment at three years with perioperative apalutamide plus hormone therapy compared with surgery alone1Results evaluated outcomes versus surgery alone, building on the primary results presented at ASCO 20261 BEERSE, BELGIUM , Oct. 24, 2026 (GLOBE NEWSWIRE) -- Johnson & Joh
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Ukraine restores Starlink speeds after week of front-line disruptions
Just now
Hundreds of soldiers sent to Milan as protesters march across Europe
Just now
PCSO Lotto Results | October 24, 2026
1h ago
The Ultimate Send-off to Summer: CSTS Debuts Global Entertainment IP PremierX at New York's Pier 17, Ushering in a New Era of Live Entertainment
1h ago